This understanding will lead, in turn, to better outcomes and decisions in treatment and management, both in the clinic and in the life cycle of drug development. The skin is a common target for adverse drug events and even mild rashes can be part of life-threatening syndromes.
prečítať celé
This understanding will lead, in turn, to better outcomes and decisions in treatment and management, both in the clinic and in the life cycle of drug development. The skin is a common target for adverse drug events and even mild rashes can be part of life-threatening syndromes.
Skryť popis